anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The efficacy of Endari in sickle cell disease was evaluated in a randomized, double-blind, placebo-controlled, multi-center clinical trial entitled "A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia" [NCT01179217] (see Table 3).

The clinical trial evaluated the efficacy and safety of Endari in 230 patients (5 to 58 years of age) with sickle cell anemia or sickle β0-thalassemia who had 2 or more painful crises within 12 months prior to enrollment. Eligible patients stabilized on hydroxyurea for at least 3 months continued their therapy throughout the study. The trial excluded patients who had received blood products within 3 weeks, had renal insufficiency or uncontrolled liver disease, or were pregnant (or planning pregnancy) or lactating. Study patients received Endari or placebo for a treatment duration of 48 weeks followed by 3 weeks of tapering.

Efficacy was demonstrated by a reduction in the number of sickle cell crises through Week 48 and prior to the start of tapering among patients that received Endari compared to patients who received placebo. This clinical benefit was observed irrespective of hydroxyurea use. A sickle cell crisis was defined as a visit to an emergency room/medical facility for sickle cell disease-related pain which was treated with a parenterally administered narcotic or parenterally administered ketorolac. In addition, the occurrence of chest syndrome, priapism, and splenic sequestration were considered sickle cell crises. Treatment with Endari also resulted in fewer hospitalizations due to sickle cell pain at Week 48, fewer cumulative days in hospital and a lower incidence of acute chest syndrome. 

The recurrent crisis event time analysis (Figure 1) yielded an intensity rate ratio (IRR) value of 0.75 with 95% CI= (0.62, 0.90) and (0.55, 1.01) based on unstratified models using the Andersen-Gill and Lin, Wei, Yang and Ying methods, respectively in favor of Endari, suggesting that over the entire 48-week period, the average cumulative crisis count was reduced by 25% from the Endari group over the placebo group.
Probiotic 1: A dietary probiotic supplement which contains Bifidobacterium lactis. Dose: \> 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
This applies to protocol 3 when 83 men and women with known CAD (coronary artery disease) got three vasodilators locally infused in the forearm while measuring vasoresponse (FBF). The other forearm was used as the control.
NEW MATERIAL:Kuwanon L shown by the formula. USE:An antibacterial agent. Especially effective against Gram-positive bacteria. PROCESS:A plant (e.g., Morus alba L., Morus bombycis Koidz, Morus Lhou Koidz or Morus multicaulis Perr., white bark of mulberry tree, etc.) is cut thinly, defatted with an organic solvent (e.g., n-hexane, benzene, etc.) having relatively low polarity, extracted with a lower fatty acid ester, lower alcohol, etc., filtered, the filtrate is dried under reduced pressure, to give purple red powder, which is subjected to column chromatography by a conventional procedure, impurities are removed, to give a fraction containing kuwanon L. This fraction, for example, is subjected to partially collecting thin layer chromatography of silica gel, high-speed liquid chromatography, so that it is isolated and purified, to give kuwanon L. The root bark of the plant is preferable as the plant, it is dried fully, powdered and used.
CASE: This case demonstrates a 2-year-old boy with a rare benign supraclavicular mass diagnosed as neuromuscular choristoma through open biopsy. Postoperatively, he underwent semiannual surveillance with ultrasound without development of neurological complaints, limb deformity, or recurrence at 2-year follow-up.
CONCLUSION: Neuromuscular choristoma involving the brachial plexus is a rare tumor that should be in the differential diagnosis of pediatric peripheral nerve-based tumors. The intimate association with neural elements limits complete resection. Therefore, open biopsy with partial resection is recommended. While postoperative fibromatosis may occur, open biopsy remains the gold standard for definitive diagnosis. Ultrasound can be used to monitor recurrence.
Within the scope of this non-interventional observational study, the quality of life of rhinosinusitis patients under self-medication with the 1,8 - cineole preparation Sinolpan® or Sinolpan® forte (Sinolpan® group) or with a nasally applied α-sympathomimetic (control group) is investigated during conditions of daily life. Patients who seek advice from a pharmacy regarding the treatment of their symptoms and who choose Sinolpan® (forte) or a nasal α-sympathomimetic can participate in this study and are asked to complete a questionnaire before and after the treatment. For organizational reasons, the recruitment of patients for the Sinolpan® group (planned number of patients: 500) or the control group (planned number of patients: 50) is conducted in different pharmacies.

The primary objective of this anonymous data collection is to assess the quality of life in patients with rhinosinusitis. The German version of the Rhinosinusitis Quality of Life questionnaire, which was only recently validated in a doctoral thesis, is used for this purpose. Additionally, for patients in the Sinolpan® group who also suffer from bronchitis, the bronchitis severity score is determined. In addition, data on side effects and tolerability of the treatment as well as on patients' satisfaction are collected.
Includes dissection, traumatic transection and other isolated aortic lesion cohorts. Subjects enrolled for treatment with the TBE device with proximal implantation in aortic Zone 2.
Heart failure (HF) with preserved ejection fraction (HFpEF) disproportionately afflicts Veterans and is the leading cause of hospitalization and mortality within the VA Health Care System. One chief symptom of HFpEF is severe exercise intolerance, an important predictor of quality of life, functional capacity, and mortality. In these patients, severe exercise intolerance is attributable to a disease-related loss of "peripheral vascular control," as evidenced by a marked attenuation in exercising skeletal muscle blood flow. Loss of peripheral vascular control is manifested as dysfunctions of the autonomic nervous system (ANS) and vasodilatory ability of the microvasculature, thereby restraining skeletal muscle blood flow and O2 delivery and limiting the capacity for sustained physical activity. This research proposal aims to elucidate peripheral vascular control mechanisms responsible for inadequate skeletal muscle blood flow and exercise intolerance in patients with HFpEF. In addition, there is some indication that aerobic exercise training may improve peripheral vascular function in HFpEF , though the mechanisms have yet to be elucidated. Thus, an additional aim of this research proposal is to evaluate peripheral vascular control mechanisms of skeletal muscle blood flow and exercise tolerance following 8 weeks of exercise training in patients with HFpEF. To test this, the initial phase will involve a cross-sectional comparison of patients with HFpEF (n=35) and age and sex-matched healthy controls (n=35), followed by an interventional phase where only patients with HFpEF will enter 8 weeks of exercise training. It is anticipated that knowledge gained will (a) improve the understanding of HFpEF pathophysiology and (b) determine the efficacy of a unique exercise training modality to restore functional capacity and exercise tolerance in patients with HFpEF.
The invention discloses a preparation method and application of an N-heterocyclic thiosemicarbazide mixed valence copper complex, wherein the chemical formula of the copper complex is [ Cu ]  II   2  (L)  2  (Cl)  2  Cu  I  (Cl)]Wherein L is (1) Z ,2 E ) -N-methyl-2- (phenyl (pyridin-2-yl) methylene) hydrazinolhioimino. The copper complex has mild synthesis conditions and high target yield. In vitro MTT activity research shows that the anticancer capability of the copper complex is obviously superior to that of cisplatin, and the copper complex shows micromolar anticancer activity. The copper complex also shows good cell inhibition in a three-dimensional A549 sphere model. Cell scratch experiments show that the copper complex has good anti-cancer cell migration capability. It was found through proteomic experiments that the copper complex performs its anticancer ability by inhibiting energy metabolism of cancer cells. The copper complex of the invention not only can be used for treating cancers, but also has the capability of resisting cell migration and has wide application prospect.
PROBLEM TO BE SOLVED: To obtain a therapeutic agent for bone disease which can increase calcium concentration in osseous tissue, DNA concentration, zinc concentration and alkaline phosphatase activity and has excellent bone formation promotive effect by formulating zinc acexamate. SOLUTION: This medicine contains zinc acexamate of the formula as an active ingredient. Zinc acexamate is obtained by mixing acexamic acid with zinc in the proportion of 2:1 and then reacting the mixture at room temperature. As this medicine has extremely low toxicity and side effect and is dissolvable into water and organic solvents, it is applicable as broad preparations for oral or parenteral administration. It is useful as therapeutic agents for diseases caused by osteoporosis, osteomalacia and osseous metabolic disorder. When orally administrated, it is administrated at a dose of 1-2,000mg/day, preferably 100-600mg/day. 1-4 times a day.
An efficient and secure process by which users may enter sensitive information into an electronic information system. When information is required from a user, the electronic information system may be configured to generate a unique access link (uniform resource locator, or URL) for that user. The link may be sent to the user via electronic communication, such as a text message or email. When the user follows the link with a web browser, the system prompts the user to enter an additional piece of personal information that is not known to the general public. Once identity is verified, the user may be required to electronically sign agreements. The user is then prompted to enter the required information. This may allow a user to deposit sensitive information into the system without requiring the user to provide full login credentials.
The present invention relates to a pure Chinese medicine oily fine powder preparation for treating incurable carbuncles, ulcers and sore toxins and a preparation method thereof. The pure Chinese medicine oily fine powder preparation is prepared from pure traditional Chinese medicinal materials including honeysuckle, nidus vespae, musk, borneol, dragon blood, pearly, dried alum, realgar, cinnabar, stigma croci, calcined gypsum, etc. through the processes of crushing by an iron medical crusher, sieving by a fine-mesh sieve to obtain fine medicinal powder, stirring by seasoning matter, etc. The pure Chinese medicine oily fine powder preparation can be directly spread on affected parts. The present invention has the efficiency of eliminating toxic materials, dispelling stasis, relieving inflammation, dredging channels, removing stasis, removing putrid tissues, promoting the growth of new tissues and removing ulcers and performs the functions of promoting tissue regeneration, strengthening sinew, activating blood circulation to dissipate blood stasis, regulating qi, removing toxins and promoting quick healing of sore surfaces. The present invention is an externally spreading pure Chinese medicine oily fine powder preparation for treating incurable carbuncles, ulcers and sore toxins, which has the advantage of high cure rate.
Compositions and methods for modifying one or more biologic targets are provided. Suitable targets include cells, DNA, proteins, enzymes, and/or a subject in need thereof. The compositions may exist as a monomer or multimer and are active in a biologic environment with enhanced activity in hypoxic environments and, thus, exhibit improved specificity for hypoxic biologic targets (e.g., tumorigenic cells and those undergoing uncontrolled cell growth). A composition typically comprises a complex with an overall charge of 2+ or greater having at least one ruthenium atom attached to a redox active ligand. The redox active ligand helps maintain separation of more than one ruthenium atom. Suitable compositions may further include a terminal ligand comprising a heterocyclic aromatic compound. When provided to a biologic target, the composition modifies the biologic target and no additional compounds need be provided. Suitable compositions are typically catalytic and regenerative in the presence of a reducing agent.
The present invention relates to emulsions of oil and at least one biologically active protein and/or at least one biologically active peptide. The bioactive protein/peptide is typically extracted from milk, and the oil is typically an edible oil. The invention also relates to a method of producing the emulsion of the invention. The invention also relates to a package suitable for storing and transporting the emulsion until the application of the mixture. Conveniently, the packaging allows the emulsion to be provided in a single use, pre-dose, ready-to-use form. Advantageously, the emulsion is both stable and allows the activity of the biologically active protein/peptide to be substantially retained.
BACKGROUND: Low back pain (LBP) is the leading cause of disability for individuals and societies globally. Prior investigations have predominantly centered around biological and psychological factors. Addressing social determinants is critical for enhancing the effectiveness and equity of pain interventions. We aimed to characterize social factors, sleep, and pain among adults with acute LBP, focusing on perceived community control.
METHODS: A community-based sample of adults with acute LBP was recruited from two cities in North Carolina, United States, and followed up at 3 months. We used descriptive statistics to characterize social factors, sleep, and pain, overall and by levels of perceived community control.
RESULTS: In total, 110/131 enrolled participants had data on perceived community control (lower scores indicate higher control). Overall, the median perceived community control was 14 (interquartile range [IQR] = 11, 15). People with high perceived community control also had, on average, higher perceived individual control, better-perceived neighborhood walkability, lower number of sites with bothersome comorbid pain, and higher sleep quality. A higher proportion of participants with high perceived community control were of male sex, White race, and had a higher socioeconomic position.
CONCLUSIONS: Community control and related constructs may be further explored in future intervention development as potentially modifiable social factors that may reduce pain burden.
PURPOSE:To obtain a preventive and therapeutic agent for infection with pathogenic germs for cultured aquatic animals capable of activating biophylactic mechanisms of the animals and preventing and treating infectious diseases with the pathogenic germs by adding the preventive and therapeutic agent to cultured aquatic animals, especially fishes or crustaceans. CONSTITUTION:A preventive and therapeutic agent for infection of cultured aquatic animals with pathogenic germs is composed of an undenatured lactoferrin(LF), lactoperoxidase(LPO) or a mixture thereof, preferably the LF and LPO separated from milk of, e.g. a human, cattle, sheep, goat, horse, dog or cat. The above-mentioned agent in an amount of 0.0001-1.0wt.% based on a formula feed for cultured aquatic animals such as cultured fishes or crustaceans cultured in culture ponds is normally added thereto for use. Although the preventive and therapeutic agent exhibits excellent effects even by the above-mentioned ingredient alone, its effects are synergistically enhanced by its use with an antibiotic substance or a synthetic antimicrobial agent in combination and the agent is more effective. Furthermore, the LF and LPO having various iron saturation degrees ranging from holoproteins to apoproteins can be used.
The present invention relates to a method for improving seven pathological conditions by the infusion method. The present invention includes an infusion method involving micro cell pathy for improving gangrene and cancer. The present invention includes a process for the manufacturing of Micro cell pathy pills using the odic tincture. The manufacturing of Micro cell pathy globules by odic tincture is used for the treatment of seven pathology conditions. The Micro cell pathy method is used for the treatment of seven pathology conditions. The seven pathology conditions are stagnation, inflammation, pains and numbness, positive and negative fever, suppuration (growth of tumors), gangrene, and cancer.
Patients receive sorafenib tosylate as in group 1. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
Ocular histoplasmosis is a leading cause of severe and irreversible central vision loss in middle-aged adults living in the central and eastern US. OHS has been associated with the fungus Histoplasma capsulatum, a dimorphic soil mold found in 18 to 20 states in the central and eastern US. Annually, approximately 100,000 people are thought to be at risk of vision loss caused by OHS.

This study will include OHS patients with CNV lesions no larger than 5400 microns in greatest linear diameter with classic or occult CNV extending under the geometric center of the FAZ and best-corrected visual acuity letter score between 20/40-20/200. Twenty four patients will be enrolled and the study will have 2 treatment arms with 12 patients each. The first arm will consist of 12 patients who will receive 0.3 mg of Macugen intravitreally every 6 weeks for one year. The second arm will consist of 12 patients who will receive Photodynamic Therapy (PDT) with Visudyne every 3 months for one year.
126,501. Ehrhardt, P. May 28, 1918. Protective fi l m s ; modicines, administering. - Flexible occlusive surgical dressings of the type consisting of paraffin wax prepared by the addition of resins with or without antisepties &c. are made up in the form of candles with wicke so that the material is readily melted and applied. The candles may be of various crosssections and may have a single wick placed axially or eccentrically, or may have two or more wicks. The melted material may be applied by means of the end of the candle as indicated in Fig. 7, or may be applied by means of a brush. The candles are sterilized during manufacture by raising the temperature of the melted substance, and are cooled in an antiseptic atmosphere such as formaldehyde. The candles are coated with paraffined paper or with a solution of lacquer, wax, resin, cellulose acetate, or a volatile solvent such as alcohol. Suitable additions to the paraffin are rubber or latex, and antiseptics or medicaments such as collorgol, salol, gomenol, pyrogallic acid, chrysophanic acid, or dermatol.
Increased availability of free fatty acids impairs glucose disposal in young healthy humans. Patients with type 2 diabetes have reduced whole body glucose disposal, increased ectopic lipid deposition in skeletal muscle and the liver and impaired mitochondrial function. Recent studies suggest that lipid metabolites such as diacylglycerol (DAG), ceramides and long-chain acyl-coA represent the active mediators inducing insulin resistance. Possible targets are DAG-sensitive Proteinkinase C (PKC θ, PKC ε) which inhibit the insulin signaling cascade and ceramides which interfere with the insulin signaling cascade at Proteinkinase B/AKT. Prior studies raised controvesial evidence, thus, it is yet unclear, whether DAG or ceramides are the primary agents inducig lipid-induced insulin resistance. Therefore, the current study aims to explore the time course of the appearance of intramyocellular lipid compunds during lipid infusion in parallel assessing markers of impaired insulin action.
PURPOSE:To prevent the disturbance of agglutination by the electrostatic repulsive force among the red cells and to make possible the exact immune reaction only by the measurement of the optical concn. of a reactive liquid by destructing the red cells fixed with an antigen on the surface, dispersing the same into the reactive liquid and causing the agglutination reaction. CONSTITUTION:Pure water is added to the suspension 2 of the red cells 1 fixed with the antigen on the surface to destruct the red cells, by which the suspension 5 of the blood cell membrane is obtd. The antibody 6 is added to the suspension 5 to form the agglutinated matter by the antigen-antibody reaction. The agglutinated matter settles in the bottom of a transparent reaction vessel 3 after the reaction and therefore light is irradiated from a light source 7 via a filter 8 to the vessel 3 from one side thereof. The photoelectric output of the light transmitted through the vessel 3 is detected by a photodetector 9 on the opposite side and the presence or absence of the agglutination is detected. The discrimination or the like of the blood group such as Rh blood group having the small blood agglutination power is thus easily exactly executed without the need for treating preliminarily the blood cell sample with bromelin (a kind of protein digestive enzyme) and without measuring the agglutination pattern.
Induction chemotherapy is often used preoperatively to reduce the size, extent, or stage of the tumor, thereby making the surgery more likely to be successful. However, there are still many patients with marginal recurrence after induction chemotherapy combined with surgery. With the progress of treatment methods, high efficient and low toxicity adjuvant immunotherapy is helpful to kill the minimal residual tumor lesions. Hence, whether complete resection is still necessary for areas with tumor regression after induction chemotherapy needs further investigation. Because of the organs at risk around the nasopharynx, any treatment strategy that can reduce the scope of tumor resection is of great significance. Therefore, by comparing reduced-target resection and full-target resection after induction chemotherapy, we aim to investigate whether reduced-target resection after induction chemotherapy is not inferior to full-target resection, but it greatly reduces the risk and difficulty of surgery. Even if marginal recurrence occurs after reduced-target resection, early intervention can still be performed through closely follow-up, without affecting the overall survival of patients.

When patients enroll this study, GTV-pre-IC (Gross Tumor Volume before induction chemotherapy) was defined according to the magentic resonance imaging before induction chemotherapy and GTV-post-IC (Gross Tumor Volume after induction chemotherapy) defined according to the magentic resonance imaging after induction chemotherapy. The pSTV-pre-IC (planing Surgical Tumor Volume before induction chemotherapy) and pSTV-post-IC (planing Surgical Tumor Volume after induction chemotherapy) were the GTV-pre-IC and GTV-post-IC plus an additional 0.5-1.0 cm peripheral mucosa margin and a 2-3 mm basal margin on the surface skull base. Patiens in experiment group will receive reduced-target resection, which resection extension is according to pSTV-post-IC. While patients in control group will receive full-target resection, which is according to pSTV-pre-IC. After surgery, the acturial resection area was defined as aSTV, which would be used for quality control. If aSTV does not cover pSTV, patients will be excluded in per-protocol set.